News hVIVO plc

Equities

Delayed London S.E. Other stock markets 10:00:49 2024-05-03 EDT			5-day change	1st Jan Change
28.04 ^GBX	+0.31%		-1.59%	+17.05%

04-09	Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024
04-09	HVIVO plc Provides Revenue Guidance for the Year 2024	CI

Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024	04-09
HVIVO swings to profit and commences annual dividends as outlook rosy	04-09	AN
HVIVO plc Provides Revenue Guidance for the Year 2024	04-09	CI
Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024	04-09
HVIVO plc Reports Earnings Results for the Full Year Ended December 31, 2023	04-09	CI
European Green Transition starts trading on London's AIM market	04-08	AN
Investment firm European Green Transition plans listing on AIM	03-18	AN
HVIVO Chair and non-exec director sell 30.0 million shares	02-14	AN
Hvivo Completes Secondary Placing	02-14	MT
HVIVO directors to sell total of 14 million shares	02-14	AN
Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares	02-14	MT
Transcript : HVIVO plc, Q4 2023 Sales/ Trading Statement Call, Jan 30, 2024	01-30
FTSE 100 Ends on Three-Week High, Partly on Diageo Rebound	01-30	DJ
HVIVO shares up after "record year" across all metrics	01-30	AN
Hvivo Wins GBP6 Million Antiviral Testing Contract	01-02	MT
HVIVO inks GBP6.3 million deal to test common cold treatment	01-02	AN
New Year begins largely green amid slew of PMIs	01-02	AN
HVIVO plc Signs £6.3 Million Human Challenge Study Model	01-02	CI
Hvivo Secures GBP17 Million Contract for RSV Antiviral Drug Testing; Stock Surges	12-13	MT
HVIVO signs deal to test RSV antiviral drug candidate with study model	12-13	AN

No results for this search